Interleukin 17 (IL-17) sustains pancreatic ductal adenocarcinoma (PDAC) immunosuppression by reducing CD8+ T-cell recruitment and activation, and recruits neutrophils and stimulates NETs formation in pancreatic tumors via factors released from tumor cells. This evidence concerns the gene IL17A and neoplasm.